ReviewCurrent medicinal chemistry2025
Advances and Challenges in Molecular Docking Applied to Neglected Tropical Diseases.
Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Identification of Ellagic Acid as a Natural GPR35 Agonist for Ulcerative Colitis Therapy.Biomolecules · 2026Article
- Structure-Based Insights into Stefin-Mediated Targeting of Fowlerpain-1: Towards Novel Therapeutics forPharmaceuticals (Basel, Switzerland) · 2025Article
- Protein-Ligand Docking Simulations for Drug Discovery.Current medicinal chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of new drugs for neglected tropical diseases (NTDs) is challenging due to the complexity of parasite-host interactions, causing resistance and the scarcity of financial resources. However, computational techniques, particularly molecular docking, have made significant advancements. This approach allows for the virtual screening of large compound libraries against specific molecular targets in parasites, efficiently cost-effectively identifying potential drug candidates. On the other hand, reverse docking seeks biological targets that can interact with specific substances of interest, integrating structural data from parasitic proteins with chemical information. Integrating computational approaches with experimental data drives the discovery of new therapeutic targets and the optimization of candidate compounds. In addition, artificial intelligence and molecular docking offer an innovative approach, enhancing prediction accuracy and driving advancements in discovering new treatments for NTDs. Thus, the primary focus of this review is to present the relevance, evolution, and prospects of the use of molecular docking techniques in the discovery and design of drug candidates for neglected diseases, despite advancements, challenges persist, including the need for increased investment in research and development, validation of predictive results, and collaboration among institutions. In this study, we aim to address the significant advancements in molecular docking and how this technique, along with modern medicinal chemistry tools, has been relevant in discovering and designing drug candidates for neglected diseases.
Indexed as
Identifiers
39773039What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.